
09/12/2025
Dana’s cancer journey began in August 2022 when persistent stomach issues brought him to Saint Luke’s Community Hospital in Roeland Park, Kansas. A CT scan revealed a cancerous mass nearly completely blocking his entire colon. He was transferred to Saint Luke's North Hospital where Dr. Ben Kulow, a colorectal surgeon, performed surgeries to address the blockage.
Unfortunately, Dana’s cancer had spread to his liver, where tumors had released high serotonin levels that damaged his heart valve. Dr. Marc Roth, a gastrointestinal oncologist, prescribed lanreotide injections to help control the tumors and lower serotonin—but this was only a temporary solution.
In November 2024, Dana received open-heart surgery to replace his tricuspid valve, which was around the same time Dr. Roth started discussing LUTATHERA®, a targeted radioactive therapy specifically for neuroendocrine tumors (NETs) found in the gut or pancreas. This leading-edge treatment destroys the cancer cells causing serotonin spikes while minimizing damage to healthy tissues.
Through Dr. Sunpreet Rakhra, a radiation oncologist, Dana became Saint Luke’s first-ever LUTATHERA recipient. After two treatments, his serotonin levels dropped dramatically—from 2,200 nanograms per milliliter to a normal 170.
“It sounds scary to be the guinea pig,” Dana says, “But I actually felt honored that I had the privilege and opportunity. Hopefully this therapy can help somebody else along the way, too.”
Dana’s treatment journey has been guided by a collaborative team of diverse medical experts whose combined knowledge and specialized skills have ensured every aspect of his care is carefully managed. While there is no cure for NET, Dana has still been able to travel the world since LUTATHERA. He says it’s a blessing he’s still able to go on these adventures.
“Planning trips has been good therapy for me,” he says. “I like planning and figuring out where we’re going to go next.”
Check out Dana's full story: https://heyor.ca/CXHoHN